Evidence map›Paper›PMID 41693770›Full record

ArticleFrontiers in pharmacology2026

New pyrimidine derivatives as potential agents against hepatocellular carcinoma: design, synthesis, and

Jeanluc Bertrand, Ignacio Montorfano, Ramón Pérez-Castro, Ricardo Valdés-Valdés, Jacqueline Romero, Thalía Delgado, Iván Brito, Juan F Santibáñez, Alan R Cabrera, María Paola Vieytes and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jeanluc BertrandDepartamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Ignacio MontorfanoATACAMA-OMICS, Laboratorio de Biología Molecular y Genómica, Facultad de Medicina, Universidad de Atacama, Copiapó, Chile.
Ramón Pérez-CastroIn vivo Tumor Biology Research Facility, Centro Oncológico, Universidad Católica del Maule, Talca, Chile.
Ricardo Valdés-ValdésIn vivo Tumor Biology Research Facility, Centro Oncológico, Universidad Católica del Maule, Talca, Chile.
Jacqueline RomeroLaboratorio de Investigaciones Biomédicas, Facultad de Medicina, Universidad Católica del Maule, Talca, Chile.
Thalía DelgadoDepartamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
Iván BritoDepartamento de Química, Facultad de Ciencias Básicas, Universidad de Antofagasta, Antofagasta, Chile.
Juan F SantibáñezGroup for Molecular Oncology, National Institute of Republic of Serbia, University of Belgrade, Institute for Medical Research, Belgrade, Serbia.
Alan R CabreraDepartamento de Química Inorgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
María Paola VieytesATACAMA-OMICS, Laboratorio de Biología Molecular y Genómica, Facultad de Medicina, Universidad de Atacama, Copiapó, Chile.
Javier EcheverríaDepartamento de Ciencias del Ambiente, Facultad de Química y Biología, Universidad de Santiago de Chile, Santiago, Chile.
Cristian O SalasDepartamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago, Chile.
César EcheverríaATACAMA-OMICS, Laboratorio de Biología Molecular y Genómica, Facultad de Medicina, Universidad de Atacama, Copiapó, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sorafenib is a tyrosine kinase inhibitor (TKI) used to treat hepatocellular carcinoma (HCC), but this drug causes clinically significant toxicities in approximately 50% of patients. Given the high frequency and severity of these side effects, it is necessary to develop new, safer drugs to treat this cancer. Purpose: Novel 2,6,9-trisubstituted pyrimidine derivatives were synthesised and evaluated as potential antitumour agents for HCC. Materials and Methods: Twelve compounds ( Results and discussion: Compound Conclusion: Based on these results, this pyrimidine derivative could be an interesting compound for the design of new agents against HCC.

Indexed as

apoptosiscaspasescytotoxicityhepatocellular carcinomain vivo evaluationpyrimidine derivatives

Identifiers

PMID41693770
PMCPMC12901390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.